Beijing Shijitan Hospital affiliated to Capital Medical University
Beijing, 100038, China
NCT Number: NCT03251573
This study is going to apply neuropsychological battery tests to measure cognitive function across multiple cognitive domains in our cohort of 600 maintenance hemodialysis patients and evaluate:
1. The presence and patterns of cognitive impairment in domains of executive function, perceptual-motor function, language, learning and memory, and complex attention; 2. Clinical characteristics of participants with and without cognitive impairment; 3. the risk factors which might be related to cognitive impairment in this group of population; 4. The association between cognitive impairment and all-cause mortality, stroke and non-fatal cardiovascular events;
We hypothesize that hemodialysis patient is going to have cognitive impairment which might be associated with some risk factors. We also anticipate that cognitive impairment might have some kind of association with the clinical outcomes like all-cause mortality, stroke and other common clinical outcomes that we mentioned above.
Looking for future studies?
Notify Me50 year–80 year
All sexes
Observational
Beijing, 100038, China
Neuropsychological assessment All neuropsychological assessments were performed by the research staff that was centrally trained and certified by the study neuropsychologist to conduct the assessments before study commencement. All research staff and patients were native Chinese speakers. Neuropsychological assessment was conducted individually in a separate room on the day after a dialysis session and required on average approximately 90 minutes. Global cognitive function was screened by the Chinese Beijing version of the Montreal Cognitive Assessment (MoCA-BJ).10 The comprehensive battery of neuropsychological tests was designed to assess five cognitive domains: (1) attention/processing speed, using Symbol Digit Modalities Test and the Chinese modified version of the Trail Making Test A,11,12(2) executive function, using the Chinese modified version of the Trail Making Tests B , and a modified version of the Stroop Color-Word Test;13 (3) verbal memory, using the Chinese version of the Auditory Verbal Learning Test for short-delay and long-delay free recall14 and Complex Figure for visual memory (delayed recall test; Chinese version);12 (4) language, using the Chinese modified versions of Boston Naming Test (the 30-item version) and Animal Fluency Test;15,16and (5) visuospatial function, using the Rey-Osterrieth Complex Figure (copy test).17,18 Depression was assessed using the Hamilton Depression Scale, with scores ranging from 0 to 63 and a score of 7 or above suggested as the optimal cutoff for suspected depression.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
one are of patients were exposed to cognitive impairment
Time frame: This measurement is going to be completed within 3 months after the first participant enrolls.
This study is going to apply neuropsychological battery tests to measure cognitive function across multiple cognitive domains
Beijing Shijitan Hospital, Capital Medical University
Other
The Cohort Study of Cognitive Impairment and Its Association With Clinical Outcomes in Chinese Maintenance Hemodialysis Patients
Acronym: CODE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05462977
Affect, Alzheimer Disease
Greensboro, North Carolina, United States
View Trial DetailsNCT05060159
Brain Diseases, Brain Edema
Mexico City, México City, Mexico
View Trial DetailsNCT03382444
Brain Diseases, Central Nervous System Diseases
Salford, Greater Manchester, United Kingdom
View Trial DetailsNCT06902753
Alzheimer Disease, Behavior
View Trial Details